Impacts on Peri-procedure Outcome of Patients with Acute Coronary Syndrome Undergone Percutaneous Coronary Intervention when Combined with Intravascular Tirofiban Administration

WANG Qilin,WANG Qibing,XU Shikun,WANG Xiangfei,ZHANG Feng,YAN Wei,QIAN Juying,FAN bing,GE Junbo
DOI: https://doi.org/10.3969/j.issn.1008-6358.2007.05.004
2007-01-01
Abstract:Objective:To explore the effects of introvascular administration of tirofiban compared with the standard application in patients with acute coronary syndrome(ACS)peri-procedure of percutaneous coronary intervention.Methods:Fifteen ACS patients who were to receive or receiving primary PCI were assigned to intravenous tirofiban application by recommended dose if there were in high risk of target vessel thrombosis or slow-flow.The patients were observed on instant new thrombosis,thrombus load,TIMI grade,main adverse cardiac events(MACE)and haemorrhage complications during hospitalization.Results:Totally 15 ACS patients(13 males,2 females,aged 44-75 years)were observed in the study.During PCI,all the target vessels showed improvement of TIMI flow grade from TIMI 0-2 to TIMI 3,disappearance of previous culprit thrombus on immediate angiography after tirofiban administration for 15-20min.The clinical general conditions of 14 patients were stable and evidently improved with no MACE and haemorrhage complications,while one patient died of cardiac shock complicating multi-organ failure during hospitalization.Conclusion:In patients of ACS with high risk of target vessel thrombosis or low TIMI grade primary PCI,intravenous or intracoronary tirofiban administration may be favorable for myocardial reperfusion and reduction in MACE complicating peri-procedure thrombosis.
What problem does this paper attempt to address?